Clinical Trials Logo

Clinical Trial Summary

Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer. The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases circulating levels of SHBG more than lifestyle intervention (LI) with or without intermittent caloric restriction (ICR) after 6 months in women at increased risk of breast cancer (i.e., healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or with > 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models or with a recently resected intraepithelial neoplasia of the breast (IEN). The secondary aims are: - to verify whether ICR significantly modulates primary and secondary endpoints such as Homeostasis Model Assessment (HOMA) index, immune and inflammatory markers, lipid profile, Adiponectin/Leptin (A/L) ratio, quality of life (QoL), Body mass index (BMI), fat body composition, safety and toxicity; - to verify whether LDT significantly modulates secondary endpoints, such as HOMA-index, immune and inflammatory markers, lipid profile, A/L ratio, QoL, BMI, fat body composition, safety and toxicity; - to investigate differences in microbiome composition by arms and the effect of changes in microbiome on QoL taking into account circulating biomarkers, cytokines, immune modulators, and inflammatory proteins in serum; - to investigate MD (Mammographic Breast Density) changes by LDT vs. LI, with or without ICR. This aim will be performed in a subgroup of participants (not all the participants will undergo mammography due to younger age).


Clinical Trial Description

Italian, multicenter, phase II, biomarker trial. A total of 200 women aged 18-70 years will be randomly assigned (1:1:1:1) to one of the four intervention arms Arm 1: Low dose Tamoxifen (LDT) i.e. 10 mg every other day; Arm 2: Low dose Tamoxifen (LDT) + Intermittent Caloric Restriction (ICR); Arm 3: Lifestyle intervention (LI) using a step counter; Arm 4: Lifestyle intervention (LI) using a step counter + Intermittent Caloric Restriction (ICR). Participants will be stratified by center and by disease status (high risk vs. previous IEN) and intervention will last six months for all arms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06033092
Study type Interventional
Source European Institute of Oncology
Contact Bernardo Bonanni, MD
Phone +39025749022
Email bernardo.bonanni@ieo.it
Status Not yet recruiting
Phase Phase 2
Start date May 2024
Completion date July 31, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02889458 - Hong Kong Breast Cancer Study
Completed NCT00757302 - Intraoperative Gamma Camera for Breast Cancer Surgery Phase 3
Active, not recruiting NCT03216421 - Intraoperative Radiation Therapy (IORT) in DCIS N/A
Completed NCT03775213 - Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) N/A
Active, not recruiting NCT00605982 - Breast MRI as a Preoperative Tool for DCIS N/A
Enrolling by invitation NCT04365114 - Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
Completed NCT04248179 - The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. Phase 4
Withdrawn NCT05032079 - Subzero and Scorpion Trial N/A
Recruiting NCT05218044 - Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ N/A
Active, not recruiting NCT01644669 - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® N/A
Recruiting NCT06133647 - Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
Completed NCT01815476 - The Prone Breast Radiation Therapy Trial N/A
Terminated NCT02137252 - Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Phase 2
Terminated NCT01060345 - A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ Phase 2
Recruiting NCT00669747 - Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Phase 2
Completed NCT00742222 - Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Phase 4
Active, not recruiting NCT02909426 - The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
Recruiting NCT02928978 - Ruxolitinib for Premalignant Breast Disease Phase 2
Completed NCT03375892 - The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure N/A
Withdrawn NCT03437915 - BrUOG 351: PRE-OPERATIVE APBI USING NIBB N/A